A standard approach to assess targeted lipid nanoparticle (LNP) delivery is to encapsulate GFP mRNA and compare GFP expression in the presence or absence of the targeting ligand.
Our CD8-eGFP-LNP has been developed as a benchmark formulation for evaluating CD8⁺ T-cell–specific delivery in in vivo CAR-T and T-cell–focused studies. This material has been adopted by multiple research partners as a reference for targeted delivery performance.
Key characteristics:
- >90% LNPs are conjugated with CD8 binder in the correct conformation
- >80% CD8⁺ T-cell–specific transfection
The CD8-eGFP-LNP provides a robust platform to support development and comparison of next-generation targeted LNPs.
If your work involves in vivo delivery to T-cell subsets or targeted mRNA delivery optimization, we’d be happy to discuss how this benchmark material can support your research.